Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer
arcticnovartis
- Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease1
- Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival*1
- Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile1
- People dia